CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Capmatinib (INC280)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02750215
NCT02750215Phase 2Completed
CompareCT.gov

A Phase 2 Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

Massachusetts General Hospital·interventional·Posted Apr 25, 2016·Updated Mar 14, 2022

In Brief

A Phase 2 clinical trial evaluating Capmatinib (INC280) for Malignant Non-small Cell Neoplasm of Lung Stage IV. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This research study is studying capmatinib as a treatment for advanced non-small cell lung cancer with MET exon 14 skipping, where the participant has already received prior therapy with a MET inhibitor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Non-small Cell Neoplasm of Lung Stage IV
CountriesUnited States
CollaboratorsNovartis

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 25, 2016
Enrollment StartMay 1, 2016
Primary CompletionMay 1, 2021
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 10.2 years ago

Interventions

Capmatinib (INC280)drug

treatment with Capmatinib (INC280)